SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Wednesday reported a loss of $4.4 million in its fourth quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 14 cents.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.
The molecular diagnostic company posted revenue of $18.3 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $17 million.
For the year, the company reported that its loss narrowed to $31.4 million, or $1.09 per share. Revenue was reported as $65.1 million.
Veracyte expects full-year revenue in the range of $76 million to $84 million.
Veracyte shares have risen almost 4 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $8.04, a rise of 25 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VCYT at https://www.zacks.com/ap/VCYT
Keywords: Veracyte, Earnings Report